257 related articles for article (PubMed ID: 20412959)
1. Combined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cells.
Taylor MD; Liu Y; Nagji AS; Theodosakis N; Jones DR
J Thorac Cardiovasc Surg; 2010 May; 139(5):1224-32, 1232.e1. PubMed ID: 20412959
[TBL] [Abstract][Full Text] [Related]
2. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P
J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid cancer cells.
Catalano MG; Fortunati N; Pugliese M; Marano F; Ortoleva L; Poli R; Asioli S; Bandino A; Palestini N; Grange C; Bussolati B; Boccuzzi G
J Clin Endocrinol Metab; 2012 Jul; 97(7):E1150-9. PubMed ID: 22563106
[TBL] [Abstract][Full Text] [Related]
4. Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition.
Kakihana M; Ohira T; Chan D; Webster RB; Kato H; Drabkin HA; Gemmill RM
J Thorac Oncol; 2009 Dec; 4(12):1455-65. PubMed ID: 20009910
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer.
Jones DR; Moskaluk CA; Gillenwater HH; Petroni GR; Burks SG; Philips J; Rehm PK; Olazagasti J; Kozower BD; Bao Y
J Thorac Oncol; 2012 Nov; 7(11):1683-90. PubMed ID: 23059775
[TBL] [Abstract][Full Text] [Related]
6. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.
Bruzzese F; Leone A; Rocco M; Carbone C; Piro G; Caraglia M; Di Gennaro E; Budillon A
J Cell Physiol; 2011 Sep; 226(9):2378-90. PubMed ID: 21660961
[TBL] [Abstract][Full Text] [Related]
7. Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells.
Miller CP; Rudra S; Keating MJ; Wierda WG; Palladino M; Chandra J
Blood; 2009 Apr; 113(18):4289-99. PubMed ID: 19182209
[TBL] [Abstract][Full Text] [Related]
8. Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
Zang Y; Kirk CJ; Johnson DE
Cancer Biol Ther; 2014 Sep; 15(9):1142-52. PubMed ID: 24915039
[TBL] [Abstract][Full Text] [Related]
9. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
[TBL] [Abstract][Full Text] [Related]
10. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C
Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
[TBL] [Abstract][Full Text] [Related]
11. Loss of miR-200b promotes invasion via activating the Kindlin-2/integrin β1/AKT pathway in esophageal squamous cell carcinoma: An E-cadherin-independent mechanism.
Zhang HF; Alshareef A; Wu C; Li S; Jiao JW; Cao HH; Lai R; Xu LY; Li EM
Oncotarget; 2015 Oct; 6(30):28949-60. PubMed ID: 26334393
[TBL] [Abstract][Full Text] [Related]
12. FAT1 prevents epithelial mesenchymal transition (EMT) via MAPK/ERK signaling pathway in esophageal squamous cell cancer.
Hu X; Zhai Y; Kong P; Cui H; Yan T; Yang J; Qian Y; Ma Y; Wang F; Li H; Cheng C; Zhang L; Jia Z; Li Y; Yang B; Xu E; Wang J; Yang J; Bi Y; Chang L; Wang Y; Zhang Y; Song B; Li G; Shi R; Liu J; Zhang M; Cheng X; Cui Y
Cancer Lett; 2017 Jul; 397():83-93. PubMed ID: 28366557
[TBL] [Abstract][Full Text] [Related]
13. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
Campbell RA; Sanchez E; Steinberg J; Shalitin D; Li ZW; Chen H; Berenson JR
Eur J Haematol; 2010 Mar; 84(3):201-11. PubMed ID: 19929977
[TBL] [Abstract][Full Text] [Related]
14. Pracinostat (SB939), a histone deacetylase inhibitor, suppresses breast cancer metastasis and growth by inactivating the IL-6/STAT3 signalling pathways.
Chen J; Li N; Liu B; Ling J; Yang W; Pang X; Li T
Life Sci; 2020 May; 248():117469. PubMed ID: 32109485
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.
Premkumar DR; Jane EP; Agostino NR; DiDomenico JD; Pollack IF
Mol Carcinog; 2013 Feb; 52(2):118-33. PubMed ID: 22086447
[TBL] [Abstract][Full Text] [Related]
16. Trichostatin A promotes esophageal squamous cell carcinoma cell migration and EMT through BRD4/ERK1/2-dependent pathway.
Liu D; Liu Y; Qi B; Gu C; Huo S; Zhao B
Cancer Med; 2021 Aug; 10(15):5235-5245. PubMed ID: 34160902
[TBL] [Abstract][Full Text] [Related]
17. Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer.
Lee JK; Ryu JK; Yang KY; Woo SM; Park JK; Yoon WJ; Lee SH; Jeong KS; Kim YT; Yoon YB
Pancreas; 2011 Aug; 40(6):966-73. PubMed ID: 21487323
[TBL] [Abstract][Full Text] [Related]
18. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
Yu C; Rahmani M; Conrad D; Subler M; Dent P; Grant S
Blood; 2003 Nov; 102(10):3765-74. PubMed ID: 12893773
[TBL] [Abstract][Full Text] [Related]
19. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex.
von Burstin J; Eser S; Paul MC; Seidler B; Brandl M; Messer M; von Werder A; Schmidt A; Mages J; Pagel P; Schnieke A; Schmid RM; Schneider G; Saur D
Gastroenterology; 2009 Jul; 137(1):361-71, 371.e1-5. PubMed ID: 19362090
[TBL] [Abstract][Full Text] [Related]
20. Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines.
Spratlin JL; Pitts TM; Kulikowski GN; Morelli MP; Tentler JJ; Serkova NJ; Eckhardt SG
Anticancer Res; 2011 Apr; 31(4):1093-103. PubMed ID: 21508352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
